Background-Platelets, on activation, release vesicular particles called platelet microparticles. Despite their procoagulant activity, their functional role in platelet-vessel wall interactions is not known. Methods and Results-We examined the binding of microparticles to vessel wall components in vitro and in vivo.
A fter activation of platelets with certain stimuli, there is a release of vesicular particles called platelet microparticles. These microparticles have been shown to accelerate thrombin generation. [1] [2] [3] [4] [5] The membranes of microparticles contain platelet GPs Ib, IIb, and IIIa as well as P-selectin and thrombospondin. 6, 7 Elevated levels of microparticles have been detected in patients with disseminated intravascular coagulation, 8 unstable angina, 9 myocardial infarction, 10 coronary angiography, 10 transient ischemic attacks, 11 and diabetes mellitus 12 and during cardiopulmonary bypass. 13 Conversely, a deficiency of platelet microparticle generation leads to a bleeding disorder with isolated prolonged bleeding time. 14 In addition to their procoagulant effect, microparticles may interact with components of the vessel wall, which contributes to their prothrombotic activities. Thus, microparticles were suggested to promote platelet adhesion to subendothelium, but the precise mechanism was not elucidated. 15 Our findings demonstrate that platelet microparticles adhere to subendothelial matrix and provide a substrate for subsequent binding of platelets in a GP IIb/IIIa-dependent manner.
Methods Materials
Anti-CD42b (IgG1 mouse, clone SZ2, Immunotech) binds to platelet GP Ib. Abciximab (Reopro) was purchased from Eli Lilly. CP8 is a murine monoclonal antibody (mAb) to GP IIb/IIIa and was a generous gift from Dr Zaverio Ruggeri (Scripps Clinic, La Jolla, Calif). Integrilin (a gift from Cor-therapeutics, San Francisco, Calif) is a cyclic heptapeptide that specifically blocks GP IIb/IIIa. Anti-GP IIIa (IgG1 mouse, clone B79.7), anti-GP IIb (IgG1 mouse, clone G1.9), and rabbit anti-polyclonal GP IIb/IIIa have been described previously. 16 Control mAb K4.40 is a murine IgG1 directed against platelet GP IV. Peroxidase-conjugated goat anti-mouse IgG1 was purchased from Calbiochem. Peroxidase-conjugated protein A was obtained from Promega, and phycoerythrin-labeled anti-GP IIIa was obtained from Pharmingen. ␤ 2 -Glycoprotein (␤ 2 GPI), 17 annexin V, 18 fibrinogen, 19 fibronectin, 20 vitronectin, 21 and von Willebrand factor (vWF) 22 were isolated as previously described. Thrombin receptor peptide (SFLLRNA) was synthesized by Dr T.C. Liang (University of Texas, Houston). Recombinant human interleukin-1␤ was pur-
Platelet/Microparticle Preparation
Platelet microparticles were isolated from blood obtained by venipuncture from healthy adult volunteers in a modification of previously described methods. 2 For the preparation of microparticles, washed platelets were resuspended in medium M199 supplemented with 1 mmol/L CaCl 2 and then activated with calcium ionophore A23187 (25 mol/L) at 37°C for 10 minutes. After activation, the platelets were stirred in siliconized cuvettes for 15 minutes and then sedimented twice at 1000g for 5 minutes. The resulting supernatant, containing microparticles, was sedimented and washed twice at 10 000g for 10 minutes. The protein content of microparticles was determined by the protein assay of Bradford according to the manufacturer's instructions (Bio-Rad). Flow cytometric analysis of the microparticles was performed with a FACScan flow cytometer (Becton Dickinson) and a phycoerythrin-labeled anti-GP IIIa antibody as previously described. 2 This analysis revealed that the preparation of microparticles contained Ͼ97% microparticles and the washed platelet preparation contained Ͼ97% platelets.
Binding Assays

Microparticle/Platelet Binding to Extracellular Matrix Proteins
Substrates for binding studies were prepared in 96-well polystyrene microtiter plates (MaxiSorp F96, Nunc). A 50-L solution containing either fibrinogen (0.5 g), fibronectin (0.5 g), vitronectin (2 g), collagen (2 g), or vWF (2 g) in Tris-buffered saline (TBS) (0.15 mol/L NaCl, 0.02 mol/L Tris, pH 7.5) was added to each well and incubated at 4°C overnight. The optimal concentration of each protein for microparticle binding was determined in preliminary experiments. The plates were then blocked with 200 L TBS containing 3% BSA at 4°C for 1 hour. Microparticles were added to each well in various amounts from 0.25 to 5 g protein. After a 60-minute incubation at 37°C, nonbound microparticles were removed by 3 vigorous washes with TBS. Thereafter, the samples were fixed for 15 minutes at room temperature by the addition of 200 L freshly prepared 4% paraformaldehyde to each well. The plates were then washed 3 times and blocked with TBS containing 3% BSA at 4°C for 1 hour. Rabbit polyclonal anti-GP IIb/IIIa (dilution 1:100) in TBS containing 1% BSA was then added to each well, and the bound microparticles were detected by peroxidase-conjugated protein A and o-phenylenediamine as substrate in an ELISA reader (MR 5000, Dynatech). To correct for nonspecific binding, adsorbence due to microparticles bound to BSA was subtracted from total adsorbence. The abciximab concentration for maximal inhibition of microparticle binding to fibrinogen and especially fibronectin was found to be 50 g/mL in preliminary experiments. For inhibition assays, microparticles were incubated with either abciximab (50 g/mL), eptifibatide (Integrilin) (50 g/mL), SZ2 (20 g/mL), ␤ 2 GPI (200 g/mL), annexin V (20 g/mL), or control mAb K4.40 (50 g/mL) at 37°C for 1 hour before their addition to the wells.
Binding assays with platelets were performed as previously described with the modification of ELISA for platelet detection. 23 Platelets (Ϸ10 6 to 10 7 ) were activated with 10 mol/L thrombin receptor peptide (SFLLRNA) and added to wells coated with various proteins. For inhibition assays, activated platelets were incubated with abciximab (50 g/mL), Integrilin (50 g/mL), or CP8 (50 g/mL) at room temperature 10 minutes before their addition. The bound platelets were detected by ELISA as described for microparticles. All the experiments were performed at least 3 times.
Microparticle Binding to HUVECs and Subendothelial Matrix
Confluent monolayers of HUVECs (96-well plates, Falcon 3072) were stimulated with either thrombin receptor peptide (SFLLRNA, 100 mol/L) for 30 minutes or recombinant human interleukin-1␤ (100 pg/mL) for 4 hours at 37°C. Subendothelial matrix was prepared by removing monolayers of HUVECs cultured for 5 days with 0.02 mol/L ammonium hydroxide for 5 minutes as described by Gospodarowicz et al. 24 The wells were blocked with 3% BSA at 4°C for 1 hour, and microparticles were then added in various amounts from 0.25 to 5 g protein either to resting or stimulated HUVECs or to subendothelial cell matrix. After a 60-minute incubation at 37°C, nonbound microparticles were removed by 5 washings and aspirations of the supernatant. After the integrity of the cell monolayer had been confirmed by direct microscopy, the samples were fixed with freshly prepared 4% paraformaldehyde for 15 minutes. The bound microparticles were detected by ELISA with mAbs to GP IIb/IIIa (CP8) or GP Ib (SZ2) as primary antibodies and goat anti-mouse IgG peroxidase as secondary antibody. These experiments were repeated at least 3 times.
Platelet Binding to Surface-Immobilized Microparticles
Wells of 96-well microtiter plates (MaxiSorp F96, Nunc) were incubated with 0.2 g protein of microparticles in 50 L M199 per well at 37°C for 1 hour. After 1 washing step, the plate was blocked with TBS containing 3% BSA at 4°C for 1 hour. The binding of platelets to the surface-bound microparticles was examined in 4 different experiments: (1) "resting" platelets added in the presence of 1 mol/L PGE 1 ; (2) "activated" platelets prepared by incubation with 10 mol/L thrombin receptor peptide (SFLLRNA) at room temperature 10 minutes before their addition; (3) addition of fibrinogen (300 g/mL) before the activation of platelets; and (4) addition of activated platelets incubated at room temperature with either abciximab (50 g/mL), Integrilin (50 g/mL), CP8 (50 g/mL), SZ2 (20 g/mL), ␤ 2 GPI (200 g/mL), annexin V (20 g/mL), or control mAb K4.40 (50 g/mL) 10 minutes before their addition to the wells. In these experiments, the platelets were added at Ϸ10 6 to 10 7 platelets in 100 L M199 to each well and incubated at 37°C for 1 hour.
In dose-response assays, microparticles were coated at concentrations varying from 0.25 to 5 g protein of microparticles per well. After 1 washing step, the plate was blocked with 3% BSA for 1 hour, and Ϸ1.25ϫ10 6 activated platelets were added to each well. The subsequent steps were the same as described for microparticles. Because the polyclonal anti-GP IIb/IIIa antibodies recognize both platelets and microparticles, the adsorbence due to antibodies bound to surface-coated microparticles was subtracted from the total adsorbence. Each of these experiments was performed at least 3 times.
SDS-PAGE and Immunoblotting
Substrate-bound microparticles were solubilized in boiling TBS containing 2% SDS and 5% mercaptoethanol, subjected to SDS-PAGE, and transferred electrophoretically to PVDF membranes, and the platelet GP IIb was identified by immunoblotting with an mAb to GP IIB (G1.9).
Radioactive Labeling of Microparticles
Microparticles isolated from 1 U blood were resuspended in 250 L PBS containing 250 Ci 51 Cr and incubated for 60 minutes. The 51 Cr-labeled microparticles were then washed 3 times by centrifugation at 10 000g and resuspended in HEPES-buffered saline. The radioactivity of the labeled microparticles was assessed by a gammacounter, LKB-Wallac Clini Gamma 1272 (Wallac Oy). The labeling efficiency of microparticles with 51 Cr was Ϸ7%.
Adhesion of Microparticles in a Rabbit Model of Endothelial Injury
New Zealand White rabbits (Ϸ3 kg) were anesthetized with ketamine and xylazine percutaneously, and the abdominal aorta and iliac arteries were surgically exposed in a modification of previously described methods. 18 A balloon catheter with a balloon length of 20 mm was introduced into the abdominal aorta Ϸ1 cm above the aortic bifurcation. The catheter was forwarded to place the balloon into one of the iliac arteries just below the aortic bifurcation. The balloon was inflated 5 times to a pressure of 8 atm for 30 seconds with intervals of 30 seconds. After immediate removal of the balloon, 51 Cr-labeled microparticles in 3 mL HEPES-buffered saline (Ϸ1200 g protein, Ϸ2.7ϫ10 6 cpm) were injected via catheter into the abdominal aorta Ϸ1 cm above the aortic bifurcation. After 3 minutes, the rabbits were killed, and Ϸ1-cm pieces of the injured and the contralateral uninjured iliac arteries were removed. After 3 washings with physiological saline solution, the radioactivity of each piece was assessed by gamma-counter. These data were analyzed by ANOVA followed by the Bonferroni test.
Results
Microparticle Binding to Extracellular Matrix Proteins
Microparticles bound to surface-bound fibrinogen, fibronectin, and collagen I and III ( (Figure 1, Ic) . The mAb to GP Ib SZ2 (20 g/mL) or a control mAb (50 g/mL) did not affect binding of microparticles to all the examined extracellular matrix (ECM) proteins (Figure 1) . Furthermore, the anionic phospholipid-binding proteins annexin V (20 g/mL) and ␤ 2 GPI (200 g/mL) had no effect, suggesting that anionic phospholipids do not play a role in this interaction (Figure 1 ).
Microparticle Binding to Endothelium
We examined the binding of microparticles to intact monolayers of HUVECs. The bound microparticles were detected with an mAb to GP IIb/IIIa (CP8). No significant binding of microparticles to a monolayer of resting HUVECs was detected, even in the presence of fibrinogen (300 g/mL) or vWF (2 g/mL) (Figure 2 ). After pretreatment of the endothelial monolayer with thrombin receptor peptide (SFLL-RNA, 100 mol/L), microparticles did not bind to the endothelial cells in the presence of fibrinogen (300 g/mL) or vWF (2 g/mL) (Figure 2) . Similar results were obtained after stimulation with recombinant human interleukin-1␤ (100 pg/mL). Also, using an mAb to GP Ib (SZ2) to detect microparticle binding gave similar results. To further support these findings, the binding of microparticles was also assessed by means of SDS-PAGE and immunoblotting with a GP IIb mAb (G1.9). In these immunoblot studies, we could not demonstrate binding of microparticles to endothelial cells, whereas binding of microparticles to fibrinogen or fibronectin could be shown under similar conditions (Figure 3 ).
Microparticle Binding to Subendothelial Matrix
To determine whether microparticles bind to subendothelial matrix, we studied the binding of microparticles to ECM produced by cultured HUVECs. As shown in Figure 2 , microparticles bound to subendothelial matrix produced by HUVECs. This interaction was inhibited by abciximab to Ϸ50%, suggesting that microparticles bound to subendothelial matrix at least partly in a GP IIb/IIIa-dependent manner.
Adhesion of Microparticles to the Site of Endothelial Injury in a Rabbit Model
To determine whether microparticles will interact with the subendothelium in vivo, the endothelium of one iliac artery of , and vWF (E). Wells of 96-well plates were coated with either fibrinogen (0.5 g/well), fibronectin (0.5 g/well), collagen (2 g/well), vitronectin (2 g/well), or vWF (2 g/well) overnight. After blocking with 3% BSA, microparticles or activated platelets were added in various concentrations and incubated for 1 hour. Samples were then washed and fixed with paraformaldehyde. Bound microparticles or activated platelets were quantified by ELISA using polyclonal antibody to GP IIb/IIIa. Microparticles or activated platelets were incubated with various agents before addition to wells. ࡗ, Medium 199 only; Ⅺ, abciximab (50 g/L); ‚, Integrilin (50 g/mL); E, CP8 (50 g/mL); ϫ, SZ2 (20 g/mL); , ␤ 2 GPI (200 g/mL); *, annexin V (20 g/mL); ϩ, control mAb (50 g/mL). C: ࡗ, Binding to collagen I; f, binding to collagen III; ‚, binding to collagen I with abciximab (50 g/mL); Ⅺ, binding to collagen III with abciximab.
New Zealand White rabbits (nϭ3) was injured by repetitive balloon inflation. 51 Cr-labeled microparticles were infused into the abdominal aorta above the aortic bifurcation. There was a 3-to 5-fold increase in radioactivity associated with the injured site compared with the contralateral uninjured site (PϽ0.05%) (Figure 4 ).
Platelet Binding to Surface-Immobilized Microparticles
A previous study suggested that microparticles promote subsequent platelet binding to subendothelium. 15 To determine whether surface-immobilized microparticles mediate this interaction, we studied the binding of platelets to surfaceimmobilized microparticles. Our results demonstrate that resting platelets bound minimally to microparticles ( Figure  5A ). After activation, however, there was significantly increased (4-fold) binding of platelets to surface-immobilized microparticles in a dose-dependent manner ( Figure 5A and 5B). The binding of activated platelets was further increased in the presence of fibrinogen (300 g/mL) by Ϸ30% ( Figure  5A ). This binding was inhibited by abciximab (Ϸ70%), CP8 (Ϸ75%), or Integrilin (Ϸ25%) (Figure 6 ), suggesting that activated platelets bind to surface-bound microparticles in a GP IIb/IIIa-dependent manner. In contrast, mAb to GP Ib, control antibody, or anionic phospholipid-binding proteins (annexin V or ␤ 2 GPI) did not have an effect in this interaction ( Figure 6 ).
Discussion
In this study, we showed that platelet-derived microparticles bound to adhesive glycoproteins, fibrinogen, fibronectin, and Figure 2 . Binding of microparticles to endothelial cells and subendothelial matrix. Confluent monolayers of HUVECs (96-well plates) were used unstimulated or stimulated with thrombin receptor peptide. Subendothelial matrix was prepared from endothelial cell monolayers. Microparticles were added in various concentrations to different plates. After a 60-minute incubation, samples were washed and fixed with 4% paraformaldehyde. Bound microparticles were quantified by ELISA using mAb to GP IIb/IIIa. Microparticles were incubated with indicated agents before addition to different plates. ‚, Binding to resting HUVECs; ϫ, binding to resting HUVECs in presence of fibrinogen; *, binding to resting HUVECs in presence of vWF; , binding to stimulated HUVECs; ϩ, binding to stimulated HUVECs in presence of fibrinogen; E, binding to stimulated HUVECs in presence of vWF; ࡗ, binding to subendothelial matrix; Ⅺ, binding to subendothelial matrix in presence of abciximab (50 g/mL). Cr-labeled microparticles to rabbit iliac artery with (f) and without (Ⅺ) endothelial injury (PϽ0.05%). Endothelium of rabbit iliac artery was injured by repetitive balloon inflation.
51 Cr-labeled microparticles were infused in abdominal aorta, and bound microparticles were determined by assessing radioactivity in harvested iliac arteries (Ϸ1-cm pieces). Figure 5 . Binding of platelets to surface-immobilized microparticles. Ninety-six-well microtiter plates were incubated with microparticles (0.2 g protein/well) for 1 hour, then washed and blocked with 3% BSA. Platelets were added in various concentrations to surface-immobilized microparticles (A) and incubated for 1 hour. In dose-response assay (B), plates were incubated with various microparticle concentrations for 1 hour. After a washing and blocking with 3% BSA, activated platelets (1.25ϫ10 6 ) were added to each well. Bound platelets were washed and quantified by ELISA as described in Figure 1 . ‚, Binding of resting platelets; Ⅺ, binding of activated platelets; ࡗ, binding of activated platelets in presence of fibrinogen.
collagen I and III in a saturating manner, similar to platelets. Abciximab and Integrilin inhibited binding of microparticles to fibrinogen and fibronectin, suggesting a GP IIb/IIIadependent binding mechanism. However, there was only minimal inhibition of microparticle binding to collagen I and III by abciximab, suggesting that collagen is not a major ligand for platelet GP IIb/IIIa. This minimal inhibitory effect could have been due to transdominant inhibition of a collagen-binding integrin. 25 Unlike platelets, microparticles showed only minimal binding to vitronectin and vWF. This functional difference could be the result of conformational changes of GP IIb/IIIa in microparticle membranes. 26 Microparticles also bound to subendothelial matrix, but not to resting or stimulated intact monolayers of HUVECs, under similar experimental conditions. Using flow cytometric analysis, Gawaz et al 27 showed that microparticles adhered to thrombin-activated endothelial cells, which involved the GP IIb/IIIa receptor. The difference in our study results could be because the ELISA and immunoblot techniques used may not be as sensitive as flow cytometric analysis. Alternatively, the removal of the endothelial monolayer and separation into a single-cell suspension by repetitive pipetting, as done by Gawaz et al, 27 could have exposed the ECM, which could have resulted in the apparent binding of microparticles to endothelial cells. Furthermore, we could show that in a rabbit model of arterial endothelial injury, 51 Cr-labeled microparticles localized to the site of endothelial injury, emphasizing that a similar interaction might even occur in vivo under flow conditions.
A previous study suggested that microparticles promote platelet adhesion to subendothelium. 15 The precise mechanism involved in this process, however, is not clear. To test the hypothesis that ECM-bound microparticles may provide a substrate for further platelet binding, we used surface-immobilized microparticles to study platelet binding. Resting platelets bound only minimally to surface-immobilized microparticles, whereas activated platelets showed significant binding. This binding was further increased in the presence of fibrinogen and was inhibited by the GP IIb/IIIa inhibitors abciximab and Integrilin. The increased binding in the presence of fibrinogen may be partly due to the formation of platelet aggregates. These findings suggest that activation of platelets is a prerequisite for binding to microparticles, probably because platelet GP IIb/IIIa undergoes conformational changes on activation that provide binding sites for soluble fibrinogen. Fibrinogen may then act as a bridging molecule between platelet and microparticle GP IIb/IIIa. In support of this, recent investigations showed that microparticles bind fibrin 28 and soluble fibrinogen and coaggregate with platelets. 29 This interaction of microparticles with platelets may even lead to further platelet activation. 30 Platelets activated by high shear stress in arteries with severe stenosis may lead to elevated levels of microparticles in circulation. 31 Microparticles would be farther in the periphery of the blood stream than platelets because of their smaller size, according to the concept of size-dependent radial distribution of particles in flow. 32, 33 However, their membrane function seems to be comparable to that of activated platelets. Therefore, they would be more likely to bind initially to exposed subendothelial matrix, thus providing a substrate for further platelet adhesion via GP IIb/IIIafibrinogen bridging. This interaction may play a significant role in hemostasis and atherosclerosis. Figure 6 . Effect of GP IIb/IIIa inhibitors on platelet binding to surface-immobilized microparticles. Ninety-six-well microtiter plates were incubated with microparticles (0.2 g protein/well) for 1 hour, then washed and blocked with 3% BSA. Activated platelets were added in various concentrations to surface-immobilized microparticles and incubated for 1 hour. Binding of platelets was then detected as outlined in Figure 1 . Activated platelets were incubated with various agents before addition to wells. ࡗ, Medium 199 only; Ⅺ, abciximab (50 g/mL); ‚, Integrilin (50 g/mL); E, CP8 (50 g/mL); ϫ, SZ2 (20 g/mL); *, ␤ 2 GPI (200 g/mL); , annexin V (20 g/mL); ϩ, control mAb (50 g/mL).
